Reid, Ph.D., Matthew N. Bainbridge, Ph.D., Alecia Willis, Ph.D., Patricia A. Ward, M.S., Alicia Braxton, M.S., Joke Beuten, Ph.D., Lover Xia, Ph.D., Zhiyv Niu, Ph.D., Matthew Hardison, Ph.D., Richard Person, Ph.D., Mir Reza Bekheirnia, M.D., Magalie S. Leduc, Ph.D., Amelia Kirby, M.D., Peter Pham, M.Sc., Jennifer Scull, Ph.D., Min Wang, Ph.D., Yan Ding, M.D., Sharon E. Plon, M.D., Ph.D., James R. Lupski, M.D., Ph.D., Arthur L. Beaudet, M.D., Richard A. Gibbs, Ph.D., and Christine M. Eng, M.D.: Clinical Whole-Exome Sequencing for the Analysis of Mendelian Disorders Mendelian diseases are believed to be rare, yet genetic disorders are estimated that occurs at a rate of 40 to 82 per 1000 live births.1 Epidemiologic studies show that if all congenital anomalies are believed as part of the genetic load, then around 8 percent of individuals are identified as having a genetic disorder before achieving adulthood.2 Collectively, uncommon genetic disorders affect substantial amounts of persons.Sidley Austin LLP and Vedder, Price, Kammholz and Kaufman acted as legal advisors to Allscripts on the merger. Allen & Overy acted as legal advisor to Misys. Highlights of Secondary Providing and Share Buyback of Allscripts Shares possessed by Misys Regarding the the merger, Allscripts will facilitate a reduced amount of Misys’s equity stake in Allscripts from approximately 55 percent to approximately 10 percent through an underwritten secondary collateral offering and talk about buyback. This reduction in collateral stake will enable Misys to keep compliance with listing requirements of the United Kingdom listing authorities.